A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
A phase 3 trial of Nanvuranlat in biliary tract cancer, run by J-Pharma Co., Ltd., now recruiting.
Overview
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer is a phase 3 interventional study registered as NCT07265674 by J-Pharma Co., Ltd., with 480 participants planned, started 2026-05-11 and due to reach its primary completion in 2027-10. Interventions recorded: Nanvuranlat.
Similar pages
not linked directly; found by shared links- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialCombination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialAn Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.